Overt Hepatic Encephalopathy Market was valued at US$ 85.2 Mn in 2021. Global Overt Hepatic Encephalopathy Market size is expected to grow at a CAGR of 12.03 % through the forecast period.Overt Hepatic Encephalopathy Market Overview:
Hepatic encephalopathy is a neurological disease, results in liver damage which alters the level of consciousness. Development chances get increased by approximately 55% of people who are suffering from cirrhosis during clinical care. Hepatic encephalopathy (HE) is part of a spectrum of neurocognitive changes in cirrhosis. HE is divided into two broad categories based on severity, covert (CHE) and overt (CHE). Overt Hepatic Encephalopathy is associated with increased rates of hospitalizations and mortality, and poor quality of life.To know about the Research Methodology :- Request Free Sample Report Clinically, patients with OHE demonstrate global neurological deficits. In stages 2–3, motor system abnormalities are clinically apparent. These include hyper-reflexia, hypertonia, asterixis, bradykinesias, rigidity, tremors, and ataxia. Mentally (either behaviorally or cognitively), patients may be aggressive, agitated, disoriented to time and place, display bizarre behavior, have personality changes, have slurred speech, lethargic or apathetic. Overt HE is a particularly pressing problem. . Given the many targets of treatment and lack of a clear singular cause of overt HE, there is no consensus on a single best treatment. Over the past several years, high-quality studies have been conducted on the various pharmacologic therapies for HE and, as more data emerge, hopefully HE will become a much more easily treated complication of decompensated liver disease. The report explores the Global Overt Hepatic Encephalopathy Market segments (Type, Application, Method and Region). Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). The MMR market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2017 to 2021. The report investigates the Global Overt Hepatic Encephalopathy Market drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Global Overt Hepatic Encephalopathy Market contemporary competitive scenario.
Overt Hepatic Encephalopathy Market Dynamics:
Drivers: The rising number of people having cirrhosis disease is the major factor which leads to the growth of the global overt hepatic encephalopathy market. Cirrhosis is a chronic liver damage illness that can result in scarring and liver failure. Increasing consumption of alcohol has led to the increased incidence of liver disease among the people. This leads to the growth of the Global Overt Hepatic Encephalopathy Market. Growing emphasis on the development of advanced solutions by the market players resulted to driving the growth of the market during the forecast period. Restrains: High cost of rifaximin for the treatment of hepatic encephalopathy is the major factor which resulted into the restraining of the growth of the Global Overt Hepatic Encephalopathy Market. For instance, according to the National Centre for Biotechnology Information, hepatic encephalopathy is the second most common reason for hospitalization in patients suffering from liver cirrhosis, in the U.S., after ascites. The various research studies would propose long-term, probably life-long, rifaximin therapy for preventing hepatic encephalopathy recurrence, as liver cirrhosis is an irreversible disease. These all factors are expected to restrain the Global Overt Hepatic Encephalopathy Market during the forecast period. COVID-19 Impact on Global Overt Hepatic Encephalopathy Market: The COVID-19 pandemic is the one of the factors which limits the growth of the Global Overt Hepatic Encephalopathy Market. The financial status of businesses in all sectors are affected due to the coronavirus (COVID-19) pandemic which led to the imposing of lockdown in various countries across the globe. The private healthcare sector is one of the sectors, which has been majorly impacted by the pandemic. The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient’s visits, among others. The pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the Global Overt Hepatic Encephalopathy Market.Overt Hepatic Encephalopathy Market Segment Analysis:
Based on Type,The segment overt is expected to grow with the highest market share in year 2021. Due to the rise in the familiarity in liver diseases, the overt segment is expected to grow in global overt hepatic encephalopathy market. The factors such as the prevalence of cirrhosis, rising road accidental cases, increased healthcare expenditure, etc. are boosting the global overt hepatic encephalopathy market. As per the WHO report near about 30-40% of patients suffer from overt hepatic encephalopathy in the US.
Overt Hepatic Encephalopathy Market Regional Insights:
The North America region is expected to witness significant growth at a CAGR of xx% through the forecast period. The increase in the number of geriatric populations and increasing number of people suffering from cirrhosis lead to the growth of overt hepatic encephalopathy in North America region. Around 5.5 million people in the U.S are affected by cirrhosis and approximately 70% of them are likely to develop symptoms of overt hepatic encephalopathy. In addition, according to the data published in American Liver Foundation in 2017, hepatitis C infection caused by hepatitis C virus (HCV), is the leading cause of liver cirrhosis in the U.S., followed by alcohol consumption related cirrhosis, contributing to around 20% to 25% cases of liver cirrhosis. Furthermore, the Asia Pacific region projected to register a steady growth rate during the forecast period of (2021-2029) owing to the increasing rate of overt hepatic encephalopathy and increasing government initiative for healthcare reforms. Europe is also expected to rise its market share in Global Overt Hepatic Encephalopathy Market during the forecast period. The increase in the research and development activities for the treatment and management of liver disease leads to the growth of the Global Overt Hepatic Encephalopathy Market in this region. Moreover, increase in the incidence of high overt hepatic encephalopathy owing to consumption of alcohol also boosting the growth of the market. ALIVER consortium developed a novel and innovative liver dialysis machine that will help the liver to naturally regenerate and to keep patients alive and healthy until a liver donor is available. The increasing prevalence of overt hepatic encephalopathy, increasing government support, and well-developed technology are the factors responsible for the rise in demand for the Global Overt Hepatic Encephalopathy Market during the forecast period. The objective of the report is to present a comprehensive analysis of the Global Overt Hepatic Encephalopathy Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Global Overt Hepatic Encephalopathy Market dynamic, structure by analyzing the market segments and projecting the Global Overt Hepatic Encephalopathy Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Overt Hepatic Encephalopathy Market make the report investor’s guide.Global Overt Hepatic Encephalopathy Market Scope: Inquire before buying
Global Overt Hepatic Encephalopathy Market Base Year 2021 Forecast Period 2022-2029 Historical Data CAGR Market Size in 2021 Market Size in 2029 2017 to 2021 12.03% US$ 85.2 Mn US$ 211.40 Mn Segments Covered by Type • Overt • Covert by Application • Hospitals • Clinics • Medical • Research Institutes by Method • Drug Treatment • Lactulose • Pathophysiology • Prognosis • Liver transplantation Regions Covered North America • United States • Canada • Mexico Europe • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest of Europe Asia Pacific • China • S Korea • Japan • India • Australia • Indonesia • Malaysia • Vietnam • Taiwan • Bangladesh • Pakistan • Rest of APAC Middle East and Africa • South Africa • GCC • Egypt • Nigeria • Rest of ME&A South America • Brazil • Argentina • Rest of South America Overt Hepatic Encephalopathy Market Key Players are
• Alfa Wassermann • Cosmo Pharmaceuticals • Horizon Pharma • KannaLife Sciences • Ocer Therapeutics • Spherium Biomed • ASKA Pharmaceutical • Valeant • Mallinckrodt • Umecrine Cognition • Rebiotix • Norgine B.V. • Lupin Limited • Kaleido Biosciences • Bausch Health Companies Inc. • Ferring Pharmaceuticals Inc. • Abbott Laboratories • QR Science and Technology Development Co. Ltd. Frequently Asked Questions: 1] What segments are covered in the Global Overt Hepatic Encephalopathy Market report? Ans. The segments covered in the Global Overt Hepatic Encephalopathy Market report are based on Type, Application and Method. 2] Which region is expected to hold the highest share in the Global Overt Hepatic Encephalopathy Market? Ans. North America region is expected to hold the highest share in the Global Overt Hepatic Encephalopathy Market. 3] What is the market size of the Global Overt Hepatic Encephalopathy Market by 2029? Ans. The market size of the Global Overt Hepatic Encephalopathy Market by 2029 is expected to reach US$ 211.40 Mn. 4] What is the forecast period for the Global Overt Hepatic Encephalopathy Market? Ans. The forecast period for the Global Overt Hepatic Encephalopathy Market is 2021-2029. 5] What was the market size of the Global Overt Hepatic Encephalopathy Market in 2021? Ans. The market size of the Global Overt Hepatic Encephalopathy Market in 2021 was valued at US$ 85.2 Mn.
1. Global Overt Hepatic Encephalopathy Market: Research Methodology 2. Global Overt Hepatic Encephalopathy Market: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Overt Hepatic Encephalopathy Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Overt Hepatic Encephalopathy Market: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Overt Hepatic Encephalopathy Market Segmentation 4.1. Global Overt Hepatic Encephalopathy Market, By Type (2022-2029) • Overt • Covert 4.2. Global Overt Hepatic Encephalopathy Market, By Application (2022-2029) • Hospitals • Clinics • Medical • Research Institutes 4.3. Global Overt Hepatic Encephalopathy Market, By Method (2022-2029) • Drug Treatment • Lactulose • Pathophysiology • Prognosis • Liver transplantation 5. North America Overt Hepatic Encephalopathy Market (2022-2029) 5.1. North America Overt Hepatic Encephalopathy Market, By Type (2022-2029) • Overt • Covert 5.2. North America Overt Hepatic Encephalopathy Market, By Application (2022-2029) • Hospitals • Clinics • Medical • Research Institutes 5.3. North America Overt Hepatic Encephalopathy Market, By Method (2022-2029) • Drug Treatment • Lactulose • Pathophysiology • Prognosis • Liver transplantation 5.4. North America Overt Hepatic Encephalopathy Market, by Country (2022-2029) • United States • Canada • Mexico 6. European Overt Hepatic Encephalopathy Market (2022-2029) 6.1. European Overt Hepatic Encephalopathy Market, By Type (2022-2029) 6.2. European Overt Hepatic Encephalopathy Market, By Application (2022-2029) 6.3. European Overt Hepatic Encephalopathy Market, By Method (2022-2029) 6.4. European Overt Hepatic Encephalopathy Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Overt Hepatic Encephalopathy Market (2022-2029) 7.1. Asia Pacific Overt Hepatic Encephalopathy Market, By Type (2022-2029) 7.2. Asia Pacific Overt Hepatic Encephalopathy Market, By Application (2022-2029) 7.3. Asia Pacific Overt Hepatic Encephalopathy Market, By Method (2022-2029) 7.4. Asia Pacific Overt Hepatic Encephalopathy Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Overt Hepatic Encephalopathy Market (2022-2029) 8.1. Middle East and Africa Overt Hepatic Encephalopathy Market, By Type (2022-2029) 8.2. Middle East and Africa Overt Hepatic Encephalopathy Market, By Application (2022-2029) 8.3. Middle East and Africa Overt Hepatic Encephalopathy Market, By Method (2022-2029) 8.4. Middle East and Africa Overt Hepatic Encephalopathy Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Overt Hepatic Encephalopathy Market (2022-2029) 9.1. South America Overt Hepatic Encephalopathy Market, By Type (2022-2029) 9.2. South America Overt Hepatic Encephalopathy Market, By Application (2022-2029) 9.3. South America Overt Hepatic Encephalopathy Market, By Method (2022-2029) 9.4. South America Overt Hepatic Encephalopathy Market, by Country (2022-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Alfa Wassermann 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Cosmo Pharmaceuticals 10.3. Horizon Pharma 10.4. KannaLife Sciences 10.5. Ocer Therapeutics 10.6. Spherium Biomed 10.7. ASKA Pharmaceutical 10.8. Valeant 10.9. Mallinckrodt 10.10. Umecrine Cognition 10.11. Rebiotix 10.12. Norgine B.V. 10.13. Lupin Limited 10.14. Kaleido Biosciences 10.15. Bausch Health Companies Inc. 10.16. Ferring Pharmaceuticals Inc. 10.17. Abbott Laboratories 10.18. QR Science and Technology Development Co. Ltd.